Headlines about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DBV Technologies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.369306297197 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of research firms recently issued reports on DBVT. Leerink Swann set a $49.00 target price on DBV Technologies and gave the company an “outperform” rating in a research note on Monday, October 23rd. Morgan Stanley downgraded DBV Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of DBV Technologies in a research report on Monday, October 23rd. Barclays decreased their price objective on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, October 23rd. Finally, Deutsche Bank increased their price target on shares of DBV Technologies from $46.00 to $56.00 in a research report on Sunday, October 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $49.63.
DBV Technologies (NASDAQ DBVT) opened at $20.90 on Thursday. DBV Technologies has a 12-month low of $20.58 and a 12-month high of $50.57.
WARNING: This news story was published by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/12/07/dbv-technologies-dbvt-earns-daily-news-impact-score-of-0-21.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.